We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02879760
Recruitment Status : Completed
First Posted : August 26, 2016
Last Update Posted : October 6, 2020
Information provided by (Responsible Party):
Turnstone Biologics, Corp.

Brief Summary:
This is a Phase 1/2, multi-center, open-label, dose-escalation trial of Ad-MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who have completed a first standard therapy with at least 1 cycle of platinum based chemotherapy and/or at least one treatment of PD-1 or PD-L1 antibody targeted therapy.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Biological: Ad-MAGEA3 Biological: MG1-MAGEA3 Biological: Pembrolizumab Phase 1 Phase 2

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Trial of MG1 Maraba Expressing MAGE-A3 (MG1-MAGEA3), With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Pembrolizumab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC)
Actual Study Start Date : March 8, 2017
Actual Primary Completion Date : February 15, 2020
Actual Study Completion Date : May 24, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: Ad/MAGEA3, MG1-MAGEA3 and pembrolizumab

Ad-MAGEA3 prime will be administered as a single IM dose on Day 1 at 2 x 10e11 VP.

MG1/MAGEA3 boost will be administered IV on Day 15 and Day 18 by 5 cohorts: Cohort 1: Days 15 & 18 at 1x 10e10 pfu.

Cohort 2: Days 15 & 18 at 1x 10e11 pfu. Cohort 3: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 4: Day 15 at 1 x 10e11 pfu; Day 18 at 3 x 10e11 pfu. Cohort 5: Day 15 at 3x 10e11 pfu; Day 18 at 3 x 10e12 pfu. Pembrolizumab will be administered IV every 3 weeks starting on Day 22.

Biological: Ad-MAGEA3
Intramuscular injection

Biological: MG1-MAGEA3
Intravenous infusion

Biological: Pembrolizumab
Intravenous infusion

Primary Outcome Measures :
  1. Phase 1 - Toxicity as measured by adverse events [ Time Frame: 7 months ]
    To determine the maximum tolerated dose MTD/ maximum feasible dose MFD of Ad/MAGEA3 and MG1-MAGEA3 in combination with pembrolizumab

  2. Phase 2 - Objective tumour response rate (ORR) based on RECIST v1.1 [ Time Frame: 7 months ]
    To evaluate objective tumour response rate (ORR) based on RECIST 1.1

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

In order to be eligible for participation in this trial, the patient must:

  1. Have histologically or cytologically confirmed diagnosis of NSCLC (squamous or non-squamous) with positive expression of MAGE-A3 (primary or metastatic lesion).
  2. Phase 1: Have radiographic progression after treatment with at least 1 cycle of platinum-doublet chemotherapy and/or at least one treatment of PD-1 or PD-L1 antibody targeted therapy. Adjuvant therapy will count as a regimen if administered within 1 year before relapse.

    Phase 2: Have radiographic progression during or after treatment with anti-PD-1/PD-L1 antibody. Adjuvant therapy will count as regimen if administered within 1 year before relapse.

  3. Phase 1: Patients with tumors of non-squamous NSCLC histology that have a known epidermal growth factor receptor (EGFR) mutation and/or anaplastic lymphoma kinase (ALK) translocation can participate in the Phase 1 portion of the study if they have failed the appropriate tyrosine kinase inhibitor (TKI) (intolerance or documented progression of their NSCLC) and have documented progression of their NSCLC. There is no preferred order of treatment with TKI or platinum doublet therapy. If a patient is found to have one molecular alteration (either sensitizing EGFR mutation or ALK translocation), then testing for the other alteration is not required.

    Phase 2: Patients with the above ALK and EGFR targetable mutations will not be eligible for treatment.

  4. Have measurable disease based on RECIST v1.1 criteria as determined by the site study team. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions post irradiation treatment.
  5. Have at least one tumor amenable to biopsy.
  6. Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
  7. Demonstrate adequate organ function:

    1. White blood cell (WBC) count ≥3,000 cells/mm3
    2. Absolute neutrophil count (ANC) ≥1,000 cells/mm3
    3. Hemoglobin ≥8 g/dL or ≥4.96 mmol/L (correction with transfusion or erythropoietin-based therapy allowed to meet eligibility criteria)
    4. Platelet count ≥100,000 platelets/mm3 (untransfused)
    5. Total bilirubin ≤1.5 x Upper Limit of Normal (ULN) OR direct bilirubin ≤ULN for patients with total bilirubin levels >1.5 x ULN (i.e., patients with Gilberts disease)
    6. Aspartate transaminase (AST), alanine aminotransferase (ALT) ≤2.5 x ULN; ≤5.0 x ULN if patient has liver metastases
    7. Serum chemistries Sodium, Potassium, and Calcium within normal limits (WNL) or Grade 1
    8. Serum creatinine ≤1.5 x ULN or creatinine clearance ≥60 mL/min for patient with creatinine levels >1.5 institutional ULN according to Cockcroft-Gault formula
    9. Serum phosphate >0.8 mmol/L (Grade 0-1)
    10. International normalized ratio (INR) ≤1.5 x ULN unless patient is receiving anticoagulant therapy as long as prothrombin time (PT) or partial prothrombin time (PTT) is within therapeutic range of intended use of anticoagulants
    11. Activated partial thromboplastin time (aPTT) ≤1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
    12. Resting oxygen saturation on room air ≥ 90%
  8. Female patients of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  9. Female patients of childbearing potential (refer to Section 11.A.2.c) must be willing to use an adequate method of contraception as outlined in Section 11.A.2.c, starting with Day 1 through 120 days after the last dose of study medication.

    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.

  10. Male patients of reproductive potential (Section 11.A.2.c) must agree to use an adequate method of contraception as outlined in Section 11.A.2.c, starting with Day 1 through 120 days after the last dose of study medication.

    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the patient.

  11. Be willing and able to provide written informed consent for the trial.
  12. Be 18 years of age (or legal age of majority in the jurisdiction) on day of signing informed consent.

Exclusion Criteria:

The patient must be excluded from participating in the trial if the patient:

  1. Has disease that is suitable for local therapy administered with curative intent.
  2. Has had prior treatment with any MAGE-A3 vaccine immunotherapy including Ad-MAGEA3 or MG1-MAGEA3.
  3. Is currently receiving experimental therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
  4. Has had prior anti-cancer monoclonal antibody (mAb) therapy within 4 weeks prior to study Day 1 or failure to recover (i.e., to ≤ Grade 1 or to baseline status) from adverse events (AEs) due to agents administered more than 4 weeks earlier.
  5. Has been intolerant of prior PD-1/PD-L1 targeted antibody therapy for which re-treatment would expose the patient to clinically significant risk in the opinion of the investigator (please attain sponsor permission of enrollment of any patient with prior intolerance to anti-PD-1/PD-L1 antibody treatment).
  6. Has had prior chemotherapy, or targeted small molecule therapy, or radiation therapy within 4 weeks prior to study Day 1 or who has not recovered (i.e., to ≤ Grade 1 or to baseline status) from AEs due to a previously administered agent.

    Note: Patients with ≤Grade 2 neuropathy or having any alopecia are an exception to this criterion and may qualify for the study.

    Note: If patient received major surgery, they must be at least 4 weeks from surgery AND have recovered adequately from the toxicity and/or complications from the surgery prior to starting therapy.

    Note: Patients receiving prior radiation must have recovered (< Grade 1) from any acute toxicity. Patients having irreversible but not clinically significant toxicity are eligible.

    Note: Patients receiving prior lung radiation with a dose of >30 Gy must wait at least 8 weeks from the date of completion of the lung radiation before the first dose of pembrolizumab.

  7. Has received prior treatment with vesicular stomatitis virus (VSV) based viral vector.
  8. Requires use of anti-platelet or anti-coagulant therapy that cannot be safely suspended for per protocol biopsies as per standard of care.
  9. Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.

    Note: Patients with previously treated brain metastases who are stable may participate. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.

  10. Has clinically significant tumor invasion (e.g., impeding obstruction) of a major vascular structure (e.g., carotid artery) or other key anatomical structure (e.g., pulmonary airway) or clinically significant and/or rapidly accumulating ascites, pericardial or pleural effusions.
  11. Has active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  12. Has evidence of active, non-infectious pneumonitis or current radiographic evidence of pneumonitis.
  13. Has a history of interstitial lung disease.
  14. Has an active infection requiring systemic therapy.
  15. Has known active Hepatitis B (e.g., Hepatitis B surface antigen [HBsAg] reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected) virus infection.
  16. Has used anti-viral medication, within 14 days of enrollment.
  17. Has conditions likely to have resulted in splenic dysfunction (e.g., splenectomy, sickle cell anemia, radiation to the spleen >20 Gy, congenital asplenism).
  18. Has significant immunodeficiency due to underlying illness (e.g., known HIV/AIDS).
  19. Has received immunosuppressive medication (e.g., systemic corticosteroids) within 4 weeks prior to the first dose of trial treatment.

    Note: Patients must not be receiving doses of >10 mg/day of prednisone or equivalent at the time of study entry and corticosteroids may not be used for premedication.

  20. Previous solid organ or allogeneic stem cell transplant.
  21. Has uncontrolled pre-existing cardiovascular conditions and/or symptomatic cardiac dysfunction.
  22. Has >Grade 2 dyspnea and/or requirement for supplemental oxygen.
  23. Has received a live vaccine within 30 days of planned start of study therapy (Note: killed flu vaccine acceptable).
  24. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  25. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
  26. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  27. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with Day 1 through 120 days after the last dose of study medication (including pembrolizumab).
  28. History of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins.
  29. Patients with household contacts meeting any of the following criteria for study entry unless alternate living arrangements can be made, while under contact precautions (from the time of initial treatment with MG1-MAGEA3 until at least 7 days after the last dose of MG1-MAGEA3):

    1. Women who are pregnant or nursing an infant
    2. Children <1 year old; or
    3. Individuals who are severely immunocompromised (including but not limited to: bone-marrow or organ transplant recipients; individuals with human Immunodeficiency virus [HIV] infection; individuals receiving chronic immunosuppressive medication such as systemic corticosteroids).
  30. Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or Sponsor staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is given allowing exception to this criterion for a specific patient.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02879760

Layout table for location information
Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
Canada, New Brunswick
Moncton Hospital
Moncton, New Brunswick, Canada, E1C 6Z8
Canada, Ontario
Juravinski Cancer Centre
Hamilton, Ontario, Canada, L8V 5C2
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V7
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1H 8L6
University Health Network
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
Turnstone Biologics, Corp.
Layout table for investigator information
Study Director: Caroline Breitbach, PhD Turnstone Biologics, Corp.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Turnstone Biologics, Corp.
ClinicalTrials.gov Identifier: NCT02879760    
Other Study ID Numbers: Ad/MG1-MAGEA3-001 (Sandpiper)
First Posted: August 26, 2016    Key Record Dates
Last Update Posted: October 6, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Turnstone Biologics, Corp.:
Oncolytic virus
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents, Immunological
Antineoplastic Agents